Who benefits most from new esophageal cancer treatment? Most patients do, except one group.

For people with advanced esophageal cancer, a new first-line treatment combining immunotherapy (called a PD-1 inhibitor) with chemotherapy is a significant step forward. This analysis of over 4,700 patients from eight major trials shows the combination is clearly more effective than chemotherapy alone. It helps patients live longer, delays the cancer's progression, and is more than twice as likely to shrink tumors. Importantly, the risk of serious treatment-related side effects was not statistically higher than with chemo alone. The benefits were widespread. Older patients and those whose cancer had spread, even to the liver, saw similar improvements. But there's one important exception: patients whose tumors have very low levels of a protein called PD-L1 (specifically, a combined positive score of less than 1) may get only a limited benefit from adding the immunotherapy. This means that while this combo is a powerful new option for most, doctors need better tests to identify everyone who will respond, so no one misses out on the right treatment.